Enlicitide (chloride)

Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1][2][3].

Product Specifications

CAS Number

[2407527-16-4]

Product Name Alternative

MK-0616 (chloride)

UNSPSC

12352209

Target

PCSK9

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/enlicitide-chloride.html

Purity

99.63

Solubility

DMSO : 1 mg/mL (ultrasonic; warming)

Smiles

O=C([C@@]1(C)N(C([C@H](CC2=CC=C(OC)C=C2)NC([C@H]([C@@H](C)O)NC3=O)=O)=O)CCC1)NCCC4=CC=C(CN(CCCCCCN5C6=C(C=C(F)C=C6)C7=C5)C(CCC(N[C@@H](C)C(N[C@H](CNC(CCCCC[N+](C)(C)C)=O)C(N[C@H](C(N[C@@H](C7)C(N([C@]38[H])CC[C@@H]8OCC9=O)=O)=O)CC%10=CC(CN9)=CC=C%10)=O)=O)=O)=O)C=C4.[Cl-]

Molecular Formula

C82H110ClFN14O15

Molecular Weight

1586.29

References & Citations

[1]Ding FX, et al. Preparation of cyclic peptides as PCSK9 antagonist compounds: World Intellectual Property Organization, WO2019246349. 2019-12-26.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Ahamad S, et al., Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. J Med Chem. 2022 Dec 8;65 (23) :15513-15539.